Canaccord Genuity raised its price target for STAAR Surgical (NASDAQ:STAA) to $11 from $9 following the company’s second quarter results. The stock closed at $10.55 on August 2.Read More
Mackie Research Capital raised its price target for Profound Medical (TSX-V:PRN) to $4.40 from $3.30 after the company reported third quarter results. The stock closed at $1 on Thursday.
Analyst Andre Uddin writes that his new valuation is based on applying a multiple of 4.2 times enterprise value to sales on a 2019 sales estimate to $86-million, discounted back by 50%.Read More
Roth Capital Partners downgraded TearLab (NASDAQ:TEAR; TSX:TLB) to “neutral” from “buy,” citing sales transition challenges. The stock closed at 83 cents on Wednesday.
Analyst Chris Lewis writes that TearLab’s second quarter year-over-year growth of 9% was the lowest since the first quarter of 2012, prompting the company to once again lower its 2016 outlook.Read More
Nobilis Health Corp. (NYSE MKT:HLTH; TSX:NHC) reported revenue of $61.9-million for the second quarter, an increase of 27% from a year ago. In addition, net income increased to $4.8 million from $0.4 million and Adjusted EBITDA increased 23%.Read More
Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) reported revenue of $20.1-million in the second quarter, an increase of 34% from $15.1-million a year ago.
Total direct sales in the latest quarter increased by $4.4-million, or 37%, and total partnered/international sales rose by $600,000, or 21%, compared with the same period last year.Read More